Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Insilico Medicine and Collaborator Discover Novel Alzheimer's Disease Targets Through AI ...

1 September 2026 · By · Wire by Fusion42

Published

1 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

Norway

◆ Source

Read at insilico.com →

◆ Verified

Fusion42 · 1 September 2026 · Fusion42 review

Insilico Medicine and collaborators used AI-driven biology and experimental validation to identify new molecular targets linked to the NAD⁺-mitophagy axis in Alzheimer's disease, demonstrating potential early blood-based biomarkers and therapeutic targets.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

You can now access AI-identified molecular targets for Alzheimer’s linked to mitochondrial health that show promise as early biomarkers and therapies. This opens a direct path for biotech founders to develop diagnostics and treatments targeting these validated pathways.

◆ Coverage

1 source · 1 Sep 2026

◆ Related on Wire

◆ Topics

Biotechai-biologyalzheimersbiomarkersdrug-targetsmitochondria